This press release contains statements represent that forward-looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 may be. Such forward-looking statements or information may include financial and other projections as well as statements about the future plans, performance, growth, profits, operating expenses or the Company’s underlying assumptions. The words ‘may ‘, ‘would ‘, ‘could’, ‘likely’, ‘expect’, ‘anticipate’, ‘intend the belief ‘project’, ‘estimate’and other similar words or phrases, or ‘believes’forward-looking statements or information can be identified read more . People who this press release are cautioned that such statements or information are only predictions and that the company , actual future results or performance to differ materially.
Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that cause our actual results, events or developments expressed materially from the results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others , the need for capital and the results of our clinical trials, the possibility that our drug does not treat target diseases as intended, the possibility that we will not be able to assumptions for our trials in a timely manner to recruit, Risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials, the possibility that such regulatory approvals are not timely or not reach or in a manner that would be conditioned our ability hinder the development forward, risks related to the requirement that a drug linked to be safe and effective after extensive clinical studies are, our dependence on suppliers, partners and other third parties and the prospects and timing for negotiating supply agreements, corporate collaborations or licensing arrangements, our ability to attract and retain key employees , and other factors as described in detail in our filings with the Canadian securities regulatory authorities at.
Should be ready model will Flu Vaccine Mismatch Of 2007-2008 seasonal Avert.
read full text